Free Trial

Blueprint Medicines (BPMC) Competitors

$107.68
+2.29 (+2.17%)
(As of 09:51 AM ET)

BPMC vs. FTSV, TPTX, CLDX, DCPH, SDGR, ALNY, TEVA, GMAB, RPRX, and BMRN

Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Forty Seven (FTSV), Turning Point Therapeutics (TPTX), Celldex Therapeutics (CLDX), Deciphera Pharmaceuticals (DCPH), Schrödinger (SDGR), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).

Blueprint Medicines vs.

Forty Seven (NASDAQ:FTSV) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.

71.8% of Forty Seven shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Blueprint Medicines has a consensus target price of $108.00, suggesting a potential upside of 2.47%. Given Forty Seven's higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Forty Seven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forty Seven
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Blueprint Medicines
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.63

Blueprint Medicines received 379 more outperform votes than Forty Seven when rated by MarketBeat users. However, 68.12% of users gave Forty Seven an outperform vote while only 67.89% of users gave Blueprint Medicines an outperform vote.

CompanyUnderperformOutperform
Forty SevenOutperform Votes
141
68.12%
Underperform Votes
66
31.88%
Blueprint MedicinesOutperform Votes
520
67.89%
Underperform Votes
246
32.11%

Forty Seven has higher earnings, but lower revenue than Blueprint Medicines. Forty Seven is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forty Seven$15.68M293.33-$87.62M-$2.34-40.82
Blueprint Medicines$249.38M26.46-$506.98M-$4.81-21.91

Forty Seven has a net margin of 0.00% compared to Forty Seven's net margin of -102.15%. Blueprint Medicines' return on equity of -50.38% beat Forty Seven's return on equity.

Company Net Margins Return on Equity Return on Assets
Forty SevenN/A -50.38% -44.35%
Blueprint Medicines -102.15%-193.48%-42.98%

In the previous week, Blueprint Medicines had 11 more articles in the media than Forty Seven. MarketBeat recorded 11 mentions for Blueprint Medicines and 0 mentions for Forty Seven. Forty Seven's average media sentiment score of 0.72 beat Blueprint Medicines' score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company Overall Sentiment
Forty Seven Neutral
Blueprint Medicines Positive

Forty Seven has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Blueprint Medicines beats Forty Seven on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPMC vs. The Competition

MetricBlueprint MedicinesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.51B$7.00B$5.15B$8.26B
Dividend YieldN/A2.65%5.26%4.06%
P/E Ratio-21.918.92113.5113.71
Price / Sales26.46263.612,331.2272.67
Price / CashN/A32.7633.6430.81
Price / Book49.025.594.904.28
Net Income-$506.98M$146.90M$109.47M$215.78M
7 Day Performance-0.40%-0.65%-0.75%-0.99%
1 Month Performance-1.22%1.58%0.46%0.33%
1 Year Performance82.88%-4.48%2.95%3.78%

Blueprint Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTSV
Forty Seven
0 of 5 stars
$95.51
flat
N/AN/A$4.60B$15.68M-38.6757
TPTX
Turning Point Therapeutics
0 of 5 stars
$76.01
flat
N/A+0.0%$3.81B$30.83M-11.02250
CLDX
Celldex Therapeutics
1.417 of 5 stars
$35.28
+0.5%
$66.00
+87.1%
+2.2%$2.33B$6.07M-12.38160Analyst Forecast
Insider Selling
Analyst Revision
News Coverage
DCPH
Deciphera Pharmaceuticals
3.333 of 5 stars
$25.57
+0.1%
$24.17
-5.5%
+82.5%$2.21B$163.36M-11.57355Positive News
SDGR
Schrödinger
1.1117 of 5 stars
$21.74
-7.1%
$42.80
+96.9%
-42.7%$1.58B$216.67M-11.56867Gap Down
ALNY
Alnylam Pharmaceuticals
4.7666 of 5 stars
$152.78
+2.3%
$216.19
+41.5%
-18.0%$19.33B$1.83B-57.012,100Positive News
TEVA
Teva Pharmaceutical Industries
0.6912 of 5 stars
$16.82
+1.3%
$15.88
-5.6%
+136.8%$18.86B$15.85B-41.0237,851Short Interest ↑
GMAB
Genmab A/S
2.8436 of 5 stars
$27.77
-2.7%
$49.25
+77.3%
-29.1%$18.36B$2.39B23.142,204Gap Down
RPRX
Royalty Pharma
4.8697 of 5 stars
$27.46
+1.4%
$43.00
+56.6%
-16.7%$16.41B$2.36B20.4951
BMRN
BioMarin Pharmaceutical
4.9574 of 5 stars
$80.69
-0.2%
$106.11
+31.5%
-8.2%$15.32B$2.42B75.413,401Positive News

Related Companies and Tools

This page (NASDAQ:BPMC) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners